We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TJX:NYSETJX Companies, Inc. (The) Analysis

Data as of 2026-03-09 - not real-time

$158.14

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

TJX is trading at $158.14, comfortably above its 20‑day SMA of 157.46 and 50‑day SMA of 155.48, indicating a short‑term bullish bias. The 200‑day SMA sits at 141.78, providing a long‑term support cushion. Technical momentum is positive, with a bullish MACD crossover (histogram +0.08) and an RSI of 52.7, suggesting room for upside without being overbought. Volume is on an increasing trend, reinforcing the price advance toward the resistance level near $162.68. The stock’s beta of 0.37 and 30‑day volatility of 18.9% point to modest price swings relative to the market. Recent news includes a Baird analyst upgrade to an Outperform rating and a raised price objective of $172, underscoring analyst confidence.
Fundamentally, TJX delivered 8.5% revenue growth, a robust ROE of 59% and free cash flow of $3.94 bn, supporting a dividend yield of 1.07% with a modest 34% payout ratio. However, the DCF fair‑value estimate of $63.8 versus the current price signals the stock is significantly overvalued, and the forward PE of 27.9 remains high for a discount retailer. Insider selling activity adds a slight negative tone, though the dividend appears sustainable. Analyst consensus (18 analysts) rates the stock as a strong‑buy with a median target of $175, implying roughly 8‑9% upside. The company’s off‑price model continues to expand internationally, providing a growth engine beyond the mature U.S. market. Overall, the blend of strong cash generation and modest upside suggests a cautious but positive stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish technical indicators (MACD, SMA alignment)
  • Support level at $150 providing downside cushion
  • Upcoming earnings and insider sales add uncertainty

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and margins
  • Robust cash generation supporting dividend
  • Analyst price target indicating upside

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Consistent high ROE and cash flow
  • Expanding off‑price model internationally
  • Dividend yield and low payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth8.50%
Profit Margin9.10%
P/E Ratio32.4
ROE59.13%
ROA13.29%
Debt/Equity132.38
P/B Ratio17.5
Op. Cash Flow$6.9B
Free Cash Flow$3.9B

Technical Analysis

TrendBullish
RSI52.7
Support$150.27
Resistance$162.68
MA 20$157.46
MA 50$155.48
MA 200$141.78
MACDBullish
VolumeIncreasing
Fear & Greed Index100

Valuation

Fair Value$63.79
Target Price$171.78
Upside/Downside8.62%
GradeOvervalued
TypeGrowth
Dividend Yield1.07%

Risk Assessment

Beta0.37
Volatility18.88%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.